Barclays’s Champions Oncology CSBR Stock Holding History

Barclays’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80	Buy	+13	New	+$78	﹤0.01%	5209
2022 Q4	–	Sell	-1,342	Closed	-$10K	–	5282
2022 Q3	$10K	Buy	+1,342	New	+$11.2K	﹤0.01%	4293
2021 Q4	–	Sell	-818	Closed	-$8K	–	4200
2021 Q3	$8K	Sell	818 -28	-3%	-$285	﹤0.01%	4544
2021 Q2	$9K	Sell	846 -4,812	-85%	-$48.8K	﹤0.01%	4671
2021 Q1	$64K	Buy	5,658 +3,576	+172%	+$41.5K	﹤0.01%	4148
2020 Q4	$22K	Sell	2,082 -1,176	-36%	-$12.1K	﹤0.01%	4656
2020 Q3	$30K	Sell	3,258 -723	-18%	-$6.44K	﹤0.01%	4799
2020 Q2	$38K	Buy	+3,981	New	+$33.9K	﹤0.01%	5032
2019 Q2	–	Sell	-47	Closed	–	–	6975
2019 Q1	$0	Buy	+47	New	+$468	﹤0.01%	7049

Other funds holding CSBR

BMC

Battery Management Corp Boston, Massachusetts $368M AUM 28.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CSBR Position: Q2 2026 in Review

Barclays opened a new position in Champions Oncology (CSBR) in Q2 2026: 13 shares worth $80. The stake represents ﹤0.01% of the portfolio and ranks #5209 among its holdings. This is a return to the name: Barclays previously reported a position in CSBR as recently as Q3 2022.

Barclays first reported a position in CSBR in Q1 2019 and has held it in 9 quarters since. The position peaked at $64K in Q1 2021. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.

Barclays held 13 shares of Champions Oncology worth $80 as of Q2 2026.
Champions Oncology was a new Barclays position in Q2 2026.
Champions Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5209 holding.
Barclays first reported a position in Champions Oncology in Q1 2019 and has held it in 9 quarters since.
Barclays's Champions Oncology position peaked at $64K in Q1 2021.
28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.